4BIO Capital is a London-based venture capital firm focused solely on advanced therapies — including cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome — addressing high unmet medical and social needs. The firm invests in and incubates early-stage companies developing emerging treatments.
55% of their portfolio is in Biotech & Life Sciences. Deal activity increased 100% year-over-year (4 deals in the last 12 months). Their most common stage is series-a (55% of deals). Average disclosed round size is $68.8M (across 28 rounds with reported amounts).
Portfolio
25
Fund Size
—
Top Stage
Series A
Last 12 Mo
4
Team
SHIKIN GANI
EXECUTIVE ASSISTANT
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
40 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Cytospire Therapeutics | Series A | — | May 2026 |
 Ray Therapeutics | Series B | $125M | Apr 2026 |
| Cytospire Therapeutics | Series A | $61M | Jan 2026 |
 Trogenix | Series A | — | Oct 2025 |
 Trogenix | Series A | $70M | Oct 2025 |
 Actithera | Series A | $75.5M | Jul 2025 |
| Trogenix | Series A | $70M | Jan 2025 |
 March Bio | Series A | $28.4M | Oct 2024 |
| AAttralus | Series B | $201M | Feb 2024 |
| VVolnay | Series A | $28.4M | Jan 2024 |
| VViaNautis Bio | Series A | $25M | Nov 2023 |
| Ray Therapeutics | Series A | $100M | May 2023 |
| AAscend Gene Cell Therapies | Series A | $132.5M | May 2023 |
 Ascend Advanced Therapies | Series A | $132.5M | Mar 2023 |
| Ascend Advanced Therapies | Series A | $130M | Jan 2023 |
| Trogenix | Seed | — | Jan 2023 |
| Ray Therapeutics | Series A | $100M | Jan 2023 |
 Entact Bio | Series A | $81M | Dec 2022 |
 Entact | Series A | $81M | Dec 2022 |
 SparingVision | Series B | — | Sep 2022 |
 Koneksa Health | Series C | $45M | Feb 2022 |
| KKoneksa | Series C | $4M | Feb 2022 |
 Luca Science | Series B | $30.3M | Jan 2022 |
 Araris Biotech | Unknown | $24M | Jan 2022 |
| Entact Bio | Series A | $81M | Jan 2022 |
Page 1 of 2
Top Co-Investors
Abingworth LLP10 shared
Eli Lilly and Company6 shared
Deerfield6 shared
Arkin Bio Ventures6 shared
Surveyor Capital6 shared
Cancer Research Horizons5 shared
IQ Capital5 shared
MRL Ventures Fund5 shared
Brain Tumor Investment Fund4 shared
Norwest Venture Partners4 shared
venBio4 shared
Logos Capital4 shared
Takeda Ventures, Inc.4 shared
UPMC Enterprises4 shared
Vi Partners4 shared
Schroders Capital4 shared
Redalpine4 shared
Pureos Bioventures4 shared
Alexandria Venture Investments3 shared
Calculus Capital3 shared
Last updated: 20 October 2026